300
Participants
Start Date
February 22, 2017
Primary Completion Date
January 15, 2021
Study Completion Date
January 15, 2021
Gelesis200
Subject would take Gelesis200 capsules 2 times per day.
Placebo
Subject would take placebo capsules 2 times per day.
Qualiclinic Kft, Budapest
University of Copenhagen - Department of Nutrition, Exercise and Sports, Frederiksberg
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Gyula
IRCCS Policlinico San Donato, San Donato Milanese
Mountain View Clinical Research - Greer, Greer
Baptist Diabetes Associates, P.A., Miami
Metabolic Research Institute, Inc., West Palm Beach
Meridien Research, Inc - Bradenton, Bradenton
Central Alabama Research, Birmingham
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville
Radiant Research, Cincinnati
The Center for Pharmaceutical Research, Kansas City
Tarheel Clinical Research, LLC, Sugar Land
SAMCRC, San Antonio
Clinical Research Center of Nevada, Las Vegas
Rainier Clinical Research Center, Renton
University of Ottawa - Institut de Recherche de l'Hospital d'Ottawa (IRHO) (Ottawa Hospital Research Institute (OHRI)), Ottawa
Université Laval, Québec
Health&Care, s.r.o, Prague
Debreceni Egyetem Klinikai Kozpont, Debrecen
NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny, Bialystok
NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek, Lodz
MEDICOME Sp. z o.o., Oświęcim
Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznan
Centrum Badawcze Wspolczesnej Terapii, Warsaw
Oakenhurst Medical Practice, Blackburn
Ashgate Medical Practice (Research Office), Chesterfield
Aintree University Hospital, Liverpool
The James Cook University Hospital, Middlesbrough
Morriston Hospital, Swansea
Lead Sponsor
Gelesis, Inc.
INDUSTRY